Baidu
map

Brit J Surg:大肠癌术后血培养与长期肿瘤学结局之间的关联

2019-11-26 xing.T MedSci原创

由此可见,结直肠癌手术后30天内需要进行血培养的临床怀疑感染与患者较差的肿瘤学结局有关。

大肠癌患者的全身性炎症可能与复发风险增加有关。近日,外科疾病领域权威杂志British Journal of Surgery上发表了一篇研究文章,这项研究调查了在大肠癌手术后30天内进行血培养的临床可疑感染是否与长期肿瘤学结局有关。

这项基于登记处的全国队列研究纳入了所有接受手术治疗且有治愈意图的丹麦居民。这些居民在2003年1月至2013年12月期间发生大肠癌。手术后180天内出现复发或死亡的患者不包括在内。研究人员使用针对相关临床混杂因素调整的Cox回归模型分析了在初次手术后30天内采血进行的血液培养与总生存、无病生存和无复发生存之间的关联,调整的因素包括人口统计学数据、癌症分期、合并症、输血情况、术后并发症及辅助化疗。

该研究共纳入了21349例患者,其中3390例(15.9%)患者在术后30天内进行了血培养。中位随访时间为5.6年,进行过血液培养的患者全因死亡风险增加(风险比(HR)为1.27,95%CI为1.20至1.35;P<0.001),无病生存期较差(HR为1.22、1.16至1.29;P<0.001)和复发风险更高(HR为1.15、1.07至1.23;P<0.001)。

由此可见,直肠癌手术后30天内需要进行血培养的临床怀疑感染与患者较差的肿瘤学结局有关。 

原始出处:

S. K. Watt.et al.Associations between blood cultures after surgery for colorectal cancer and long‐term oncological outcomes. British Journal of Surgery.2019.https://doi.org/10.1002/bjs.11372

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1815150, encodeId=400c18151508c, content=<a href='/topic/show?id=c59e9e03792' target=_blank style='color:#2F92EE;'>#长期肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97037, encryptionId=c59e9e03792, topicName=长期肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Wed Mar 11 07:44:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375951, encodeId=48cd3e595171, content=学习了,思路很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f71699602, createdName=1de7a66em30(暂无匿称), createdTime=Thu Nov 28 16:49:11 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390796, encodeId=016b1390e960a, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540146, encodeId=46ef1540146c0, content=<a href='/topic/show?id=671f89004fc' target=_blank style='color:#2F92EE;'>#血培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89004, encryptionId=671f89004fc, topicName=血培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5f013187051, createdName=花花1370, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375894, encodeId=851d3e5894e7, content=研究很前沿,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Nov 27 08:07:04 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1815150, encodeId=400c18151508c, content=<a href='/topic/show?id=c59e9e03792' target=_blank style='color:#2F92EE;'>#长期肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97037, encryptionId=c59e9e03792, topicName=长期肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Wed Mar 11 07:44:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375951, encodeId=48cd3e595171, content=学习了,思路很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f71699602, createdName=1de7a66em30(暂无匿称), createdTime=Thu Nov 28 16:49:11 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390796, encodeId=016b1390e960a, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540146, encodeId=46ef1540146c0, content=<a href='/topic/show?id=671f89004fc' target=_blank style='color:#2F92EE;'>#血培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89004, encryptionId=671f89004fc, topicName=血培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5f013187051, createdName=花花1370, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375894, encodeId=851d3e5894e7, content=研究很前沿,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Nov 27 08:07:04 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2019-11-28 1de7a66em30(暂无匿称)

    学习了,思路很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1815150, encodeId=400c18151508c, content=<a href='/topic/show?id=c59e9e03792' target=_blank style='color:#2F92EE;'>#长期肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97037, encryptionId=c59e9e03792, topicName=长期肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Wed Mar 11 07:44:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375951, encodeId=48cd3e595171, content=学习了,思路很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f71699602, createdName=1de7a66em30(暂无匿称), createdTime=Thu Nov 28 16:49:11 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390796, encodeId=016b1390e960a, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540146, encodeId=46ef1540146c0, content=<a href='/topic/show?id=671f89004fc' target=_blank style='color:#2F92EE;'>#血培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89004, encryptionId=671f89004fc, topicName=血培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5f013187051, createdName=花花1370, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375894, encodeId=851d3e5894e7, content=研究很前沿,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Nov 27 08:07:04 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1815150, encodeId=400c18151508c, content=<a href='/topic/show?id=c59e9e03792' target=_blank style='color:#2F92EE;'>#长期肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97037, encryptionId=c59e9e03792, topicName=长期肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Wed Mar 11 07:44:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375951, encodeId=48cd3e595171, content=学习了,思路很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f71699602, createdName=1de7a66em30(暂无匿称), createdTime=Thu Nov 28 16:49:11 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390796, encodeId=016b1390e960a, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540146, encodeId=46ef1540146c0, content=<a href='/topic/show?id=671f89004fc' target=_blank style='color:#2F92EE;'>#血培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89004, encryptionId=671f89004fc, topicName=血培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5f013187051, createdName=花花1370, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375894, encodeId=851d3e5894e7, content=研究很前沿,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Nov 27 08:07:04 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1815150, encodeId=400c18151508c, content=<a href='/topic/show?id=c59e9e03792' target=_blank style='color:#2F92EE;'>#长期肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97037, encryptionId=c59e9e03792, topicName=长期肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Wed Mar 11 07:44:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375951, encodeId=48cd3e595171, content=学习了,思路很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71f71699602, createdName=1de7a66em30(暂无匿称), createdTime=Thu Nov 28 16:49:11 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390796, encodeId=016b1390e960a, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540146, encodeId=46ef1540146c0, content=<a href='/topic/show?id=671f89004fc' target=_blank style='color:#2F92EE;'>#血培养#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89004, encryptionId=671f89004fc, topicName=血培养)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5f013187051, createdName=花花1370, createdTime=Thu Nov 28 10:44:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375894, encodeId=851d3e5894e7, content=研究很前沿,受益良多, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Nov 27 08:07:04 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2019-11-27 14794e5bm67(暂无昵称)

    研究很前沿,受益良多

    0

相关资讯

香港卫生署:大肠癌筛查参与者已突破10万人

据香港《大公报》报道,香港大肠癌筛查先导计划今年8月常态化,香港卫生署9日公布,参与者已突破10万人。有参与计划的荃湾港安医院表示,已为766人进行大肠镜检查,当中30人确诊大肠癌,比例与特区政府计划整体数字相若,但也发现不少大便隐血测试结果为阳性的病人,没有预约做大肠镜检查,认为特区政府应联络相关病人,跟进情况。据报道,荃湾港安医院外科顾问医生周俊恒称,不少大便隐血测试结果为阳性的病人,没有预

李进教授:大肠癌患者迎来三线治疗新选择,国内自主研发新药爱优特®(呋喹替尼胶囊)开出首批处方

2018年11月26日,我国自主研发获批上市的抗血管生成药物爱优特?(呋喹替尼胶囊)在上海开出全球首批处方,这也标志着中国晚期大肠癌患者三线治疗有了新的选择。

小心!这样的大便,可能是大肠癌来临!

今年刚满50岁的陈先生,近半年多来大便越来越不正常,腹泻伴随轻微腹痛,一天要跑好几次厕所,有时候大便中还带有暗红色的血,还比较黏,不容易冲走。 起初以为是痔疮,并没有太在意,但腹泻和便血症状不断加重,一直未见好转,人也日渐消瘦。 最后在家人的劝说下来到我们内镜中心做了肠镜,结果让陈先生和家人如五雷轰顶:

这些息肉几乎100%会癌变!千万不要小病拖成大病!

上个月,我们收治了收治一例病人,年仅25岁 ,以大便带血就诊,内镜一查大肠,有数不清的息肉,病理显示已有癌变,追问病史,其上一代直系亲属大多死于消化道肿瘤,该患者被诊断为家族性腺瘤性息肉病(FAP) 。

小小息肉惹大祸,兄妹四人全患大肠癌!

患者王某,女,46岁,农民,因腹痛就诊。肠镜检查先是看到息肉,随后在乙状结肠发现结肠癌,肠腔狭窄,肠镜勉强通过。在口侧的乙状结肠、降结肠、横结肠见到多枚大小不等息肉。在结肠肝曲又发现一处结肠癌。肠腔狭窄, 肠镜已无法通过,于两处癌变部位取活检后退镜。

JCO:Pembrolizumab治疗难治性,微卫星不稳定性高/错配修复缺陷的转移性结直肠癌的II期开放标签研究:KEYNOTE-164

临床试验KEYNOTE-164(NCT02460198)评估了派姆单抗在已接受治疗的,转移性微卫星不稳定性高/错配修复缺陷型(MSI-H / dMMR)大肠癌(CRC)中的抗肿瘤活性。

Baidu
map
Baidu
map
Baidu
map